City

Clinical trials near Tampa, United States

Active studies with a listed research site in Tampa, United States.

12active studies

6recruiting now

4countries represented

40largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Psoriasis, Overweight or ObesityCondition

TirzepatideTreatment

United States39 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06857942See eligibility →

Recruiting nowPhase 2

A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

Adults With Overweight/Obesity and Type 2 DiabetesCondition

AT673 low dose, AT673 high doseTreatment

United States8 locations

Antag TherapeuticsSponsor

Updated 2026-09-01 · NCT07724340See eligibility →

Recruiting nowPhase 2

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Opioid Use Disorder, Opioid Use Disorder, ModerateCondition

Tirzepatide, PlaceboTreatment

United States9 locations

T. John Winhusen, PhDSponsor

Updated 2026-08-11 · NCT06651177See eligibility →

Recruiting nowNot applicable

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

Pancreatic CancerCondition

Blood Sample Collection, Tissue Sample CollectionTreatment

United States2 locations

H. Lee Moffitt Cancer Center and Research InstituteSponsor

Updated 2026-05-26 · NCT05687188See eligibility →

Recruiting nowPhase 3

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Nausea and Vomiting, ObesityCondition

Tradipitant, PlaceboTreatment

United States10 locations

Vanda PharmaceuticalsSponsor

Updated 2026-04-20 · NCT07446439See eligibility →

Recruiting nowNot applicable

FRESH-EATS Project

Dietary Behaviors, Obesity and OverweightCondition

FRESH-EATS, Lagged Intervention Control GroupTreatment

United States1 locations

University of South FloridaSponsor

Updated 2025-07-08 · NCT07053644See eligibility →

Opening soonNot applicable

Modifying Diet to Improve Gut Microbiome

ObesityCondition

DASH diet, standard American dietTreatment

United States1 locations

H. Lee Moffitt Cancer Center and Research InstituteSponsor

Updated 2025-09-10 · NCT03924778See eligibility →

Active, not recruitingNot applicable

NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors

Obesity, Childhood, CancerCondition

NOURISH-T+, Brief NOURISH-T+Treatment

United States10 locations

University of South FloridaSponsor

Updated 2026-08-12 · NCT04656496See eligibility →

Active, not recruitingNot applicable

Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools

ObesityCondition

Diabetes Prevention Program Intensive Lifestyle Intervention plus stress management training, Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topicsTreatment

United States1 locations

H. Lee Moffitt Cancer Center and Research InstituteSponsor

Updated 2026-07-30 · NCT04335799See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

Argentina, Canada40 locations

Eli Lilly and CompanySponsor

Updated 2026-07-23 · NCT07035093See eligibility →

Active, not recruitingPhase 2

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Adult Obesity, Weight ManagementCondition

ECC4703, PlaceboTreatment

United States15 locations

EccogeneSponsor

Updated 2026-06-25 · NCT07505303See eligibility →

Active, not recruitingPhase 2

A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

Obesity, Overweight or ObesityCondition

MET097, PlaceboTreatment

United States5 locations

PfizerSponsor

Updated 2026-05-29 · NCT06973720See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Tampa, United States

Current studies

Related cities